Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma

O. Obodo, O. Ige, C. Chukwu (Ikeja, Ibadan, Lagos, Nigeria)

Source: Annual Congress 2009 - Aspects of clinical asthma
Session: Aspects of clinical asthma
Session type: Thematic Poster Session
Number: 1968
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Obodo, O. Ige, C. Chukwu (Ikeja, Ibadan, Lagos, Nigeria). Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma. Eur Respir J 2009; 34: Suppl. 53, 1968

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen
Source: Eur Respir J 2003; 22: Suppl. 45, 411s
Year: 2003

Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population
Source: Eur Respir J 2004; 24: Suppl. 48, 311s
Year: 2004

A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

The ATACO study: adjustable maintenance therapy with budesonide and formoterol in a single inhaler
Source: Eur Respir J 2002; 20: Suppl. 38, 41s
Year: 2002

Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose
Source: Eur Respir J 2002; 20: Suppl. 38, 396s
Year: 2002

Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study
Source: International Congress 2018 – Asthma and drugs
Year: 2018

Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler
Source: ERJ Open Res 2016: 00106-2015
Year: 2016



Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing
Source: Eur Respir J 2003; 22: Suppl. 45, 438s
Year: 2003

Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy
Source: Eur Respir J 2003; 22: Suppl. 45, 411s
Year: 2003

Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004

Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy
Source: Eur Respir J 2010; 36: 524-530
Year: 2010



Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens
Source: Eur Respir J 2004; 24: Suppl. 48, 311s
Year: 2004

Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

Benefits of adjustable versus fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 258s
Year: 2003

Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010